Heart Condition clinical trials

Explore recruiting heart condition clinical trials.

Recruiting heart condition studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Heart Condition trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

RandomizEd trial to DEtermine the efficacy and safety of FINErenone on morbidity and mortality among heart failure patients with left ventricular ejection fraction greater than or equal to 40% hospitalized due to an episode of acute decompensated Heart Failure (REDEFINE-HF)

Poland, Czechia, Hungary, Greece, Lithuania, Germany +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

COmbiNed eFfIcacy and safety of an eaRly, intensive MAnagement sTrategy with fInerenOne and SGLT2 iNhibitor in patients hospitalized with Heart Failure (CONFIRMATION-HF)

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, placebo-controlled pragmatic study to evaluate FINerenone on clinicAL effIcacy and safeTY in patients with Heart Failure and reduced ejection fraction who are intolerant of or not eligible for treatment with steroidal mineralocorticoid receptor antagonists (FINALITY-HF)

Czechia, Hungary, Poland, Greece, Croatia, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared with Open-Label Rivaroxaban in Patients with Atrial Fibrillation (AZALEA)

Czechia, Hungary, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Heart Condition trials by city

Heart Condition in Toronto Heart Condition in Vancouver Heart Condition in Montreal Heart Condition in Calgary Heart Condition in Edmonton Heart Condition in Ottawa Heart Condition in Winnipeg Heart Condition in Quebec City Heart Condition in Hamilton Heart Condition in Kitchener Heart Condition in London Heart Condition in Halifax Heart Condition in New York Heart Condition in Los Angeles Heart Condition in Chicago Heart Condition in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease